New drug combo aims to shrink lung tumors before surgery in targeted trial
NCT ID NCT07153770
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests whether a drug called bozitinib, combined with chemotherapy, can shrink tumors in people with a specific genetic lung cancer (MET-altered) before they have surgery. About 34 adults with stage IIA to IIIC non-small cell lung cancer will receive the treatment and then have their tumors removed. The main goal is to see if the tumor has very few living cancer cells left after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.